Your browser doesn't support javascript.
Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein.
DiMuzio, Jillian M; Heimbach, Baron C; Howanski, Raymond J; Dowling, John P; Patel, Nirja B; Henriquez, Noeleya; Nicolescu, Chris; Nath, Mitchell; Polley, Antonio; Bingaman, Jamie L; Smith, Todd; Harman, Benjamin C; Robinson, Matthew K; Morin, Michael J; Nikitin, Pavel A.
  • DiMuzio JM; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Heimbach BC; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Howanski RJ; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Dowling JP; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Patel NB; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Henriquez N; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Nicolescu C; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Nath M; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Polley A; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Bingaman JL; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Smith T; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Harman BC; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Robinson MK; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Morin MJ; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
  • Nikitin PA; Immunome, Inc., 665 Stockton Drive, Suite 300, Exton, PA 19341, USA.
Vaccine X ; 8: 100098, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1203207
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Patients who recover from SARS-CoV-2 infections produce antibodies and antigen-specific T cells against multiple viral proteins. Here, an unbiased interrogation of the anti-viral memory B cell repertoire of convalescent patients has been performed by generating large, stable hybridoma libraries and screening thousands of monoclonal antibodies to identify specific, high-affinity immunoglobulins (Igs) directed at distinct viral components. As expected, a significant number of antibodies were directed at the Spike (S) protein, a majority of which recognized the full-length protein. These full-length Spike specific antibodies included a group of somatically hypermutated IgMs. Further, all but one of the six COVID-19 convalescent patients produced class-switched antibodies to a soluble form of the receptor-binding domain (RBD) of S protein. Functional properties of anti-Spike antibodies were confirmed in a pseudovirus neutralization assay. Importantly, more than half of all of the antibodies generated were directed at non-S viral proteins, including structural nucleocapsid (N) and membrane (M) proteins, as well as auxiliary open reading frame-encoded (ORF) proteins. The antibodies were generally characterized as having variable levels of somatic hypermutations (SHM) in all Ig classes and sub-types, and a diversity of VL and VH gene usage. These findings demonstrated that an unbiased, function-based approach towards interrogating the COVID-19 patient memory B cell response may have distinct advantages relative to genomics-based approaches when identifying highly effective anti-viral antibodies directed at SARS-CoV-2.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Vaccine X Year: 2021 Document Type: Article Affiliation country: J.jvacx.2021.100098

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Vaccine X Year: 2021 Document Type: Article Affiliation country: J.jvacx.2021.100098